By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.

Presentation of Q2 2022 results at the H.C. Andersen Capital webinar, August 18 at 14:00 CET
ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q2 2022 results and answer investors' questions. More information and registration can be found on the H.C. Andersen Capital events website (https://hcandersencapital.dk/event/expres2ion-biotechnologies-presentation-of-h1-2022/).

LSX Nordic Congress, September 6-7, Copenhagen, Denmark
An opportunity for investors and potential partners to meet ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander in 1-on-1 meetings. More information and registration can be found on the LSX Nordic website (https://www.lsxleaders.com/lsx-nordic-congress).

Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy
Meet ExpreS[2]ion's VP of Preclinical Development, Dr. Mette Thorn, and hear the company's preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine," in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the PIVAC-22 website (https://www.pivac22.it/).

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se